http://www.newrepublic.com/article/114072/howard-dean-obamacare-payment-board-and-k-street
Or maybe it’s not so strange to hear Dean say this. Since his career in politics ended, Dean has found a home in the K Street establishment he once held in such disdain. He’s a strategic adviser to McKenna, Long, and Aldridge, a major Washington lobbying firm whose clients have included health care and pharmaceutical companies. Dean has never registered as a lobbyist, as far as I know, but the distinction is largely illusory. In 2009, one CEO told the publication BioCentury that Dean was “very helpful” in their efforts to loosen federal regulations on drug development.” Another said that “Dean has been a great addition to our team.”
http://www.salon.com/2011/09/01/howard_dean_paid_advocate/
Dean may not be the worst of the “buckrakers,” those prototypical capital characters who exploit their name and connections without regard for principle. But his recent political forays seem to have diverged from his trailblazing left-liberal past.
As senior strategic advisor at McKenna Long & Aldridge, a heavyweight Washington lobbying firm, Dean played a prominent role representing the biotech industry during the healthcare bill debate, staking out a position on biopharmaceutical drugs that was decried by consumer groups.
“Gov. Dean was very helpful to us,” biotech CEO Jim Greenwood told a trade publication “As a physician clearly focused on healthcare, a Democrat leader and clearly to left of center, his efforts were impactful.” Greenwood is the head of the Biotechnology Industry Organization (BIO), a trade group that lobbies for the industry in Washington.
Dean is also currently one of the most prominent paid voices in a public-relations campaign on behalf of the Mujahedin-e Khalq (MEK), an obscure and controversial Iranian militant group that is aggressively lobbying the Obama administration to remove it from the official list of terrorist organizations.
= new reply since forum marked as read